Health and Healthcare

Celgene : CELG

All CELG Articles

433 Articles

Chris Lange | Sep 27, 2016 at 7:50 AM EDT

Short Sellers Increase Bets in Major Biotechs

The September 15 short interest data have been compared with the previous report, and short interest moves were upward across…

Lee Jackson | Sep 19, 2016 at 8:25 AM EDT

RBC Says These 4 Top Biotechs Could Have Big Upside Potential

An RBC report noted that although headline issues such as the Federal Reserve and the election are increasing volatility, four…

Chris Lange | Sep 14, 2016 at 10:35 AM EDT

Agios Files for Secondary Offering

Agios Pharmaceuticals has filed with the SEC regarding a secondary offering of up to $150 million of its common stock.

Chris Lange | Sep 13, 2016 at 7:05 AM EDT

Short Sellers Run for Cover From Major Biotechs

The August 31 short interest data have been compared with the previous report, and short interest decreased for most of…

Chris Lange | Sep 11, 2016 at 10:35 AM EDT

4 Key BioPharma Movers in the Past Week

Some biotech companies made impressive runs over the course of this past week. These select few stood out from the…

Chris Lange | Sep 7, 2016 at 12:10 PM EDT

Did Agios Just Speed Up Its Business Plan by 2 Years?

Celgene is making a move out of left field that has sent shares of its partner Agios Pharmaceuticals significantly higher.

Chris Lange | Aug 25, 2016 at 8:40 AM EDT

Short Sellers Increase Bets in Major Biotechs

The August 15 short interest data have been compared with the previous report, and short interest moves were mixed across…

Jon C. Ogg | Aug 18, 2016 at 12:50 PM EDT

How Much Medivation Can Really Fetch in a Buyout

Medivation has been among the top future biotech mergers for quite some time. The problem is that we still have…

Lee Jackson | Aug 15, 2016 at 10:20 AM EDT

Top Biotechs Are Among Jefferies Growth Stock Favorites

Jefferies searches for growth with reasonable valuations and upside potential. This week's picks are no exception to that rule.

Chris Lange | Aug 10, 2016 at 8:50 AM EDT

Short Sellers Run for Cover From Major Biotechs

The short interest data are out for the July 29 settlement date and short interest decreased across these selected biotech…

Lee Jackson | Aug 4, 2016 at 10:40 AM EDT

Merrill Lynch Says the Time to Put Money Into Biotech Is Now

Though these four large cap biotech stocks are cheap relative to the S&P 500, history says they won’t stay that…

Jon C. Ogg | Aug 4, 2016 at 8:55 AM EDT

Top Analyst Upgrades and Downgrades: Apollo Global, ADM, Celgene, Total, Whole Foods, Targa Resources and More

The top analyst upgrades, downgrades and initiations seen on Thursday morning include Apollo Global, ADM, Celgene, Total, Whole Foods and…

Lee Jackson | Aug 1, 2016 at 9:25 AM EDT

RBC Says Buy Big Biotechs Now for Possible Big 2016 Gains

Finally, concerns about biotech seem to be waning. An RBC research report notes that at the recent political conventions there…

Chris Lange | Jul 28, 2016 at 9:05 AM EDT

How Celgene Won With This Earnings Report

Overall, investors were content after Celgene reported its second-quarter financial results, with wins on both the top and bottom lines.

Lee Jackson | Jul 27, 2016 at 8:20 AM EDT

JPMorgan Bullish on Biotech: 3 Top Picks to Buy Now

A new JPMorgan research report says it time to buy the health care sector and sell consumer staples, which have…

1 … 10 11 12 13 14 … 29

Celgene : CELG

All CELG Articles

Short Sellers Increase Bets in Major Biotechs

RBC Says These 4 Top Biotechs Could Have Big Upside Potential

Agios Files for Secondary Offering

Short Sellers Run for Cover From Major Biotechs

4 Key BioPharma Movers in the Past Week

Did Agios Just Speed Up Its Business Plan by 2 Years?

Short Sellers Increase Bets in Major Biotechs

How Much Medivation Can Really Fetch in a Buyout

Top Biotechs Are Among Jefferies Growth Stock Favorites

Short Sellers Run for Cover From Major Biotechs

Merrill Lynch Says the Time to Put Money Into Biotech Is Now

Top Analyst Upgrades and Downgrades: Apollo Global, ADM, Celgene, Total, Whole Foods, Targa Resources and More

RBC Says Buy Big Biotechs Now for Possible Big 2016 Gains

How Celgene Won With This Earnings Report

JPMorgan Bullish on Biotech: 3 Top Picks to Buy Now

This High-Yield Emerging Funds ETF Offers International Diversification

A 71-Year-Old’s $850,000 Home Is Her Biggest Retirement Asset. Downsizing Could Add $2,250 a Month

Why The Money Guy’s 25% Savings Rule Actually Starts at 15%

A 71-Year-Old's $850,000 Home Is Her Biggest Retirement Asset. Downsizing Could Add $2,250 a Month

Why The Money Guy's 25% Savings Rule Actually Starts at 15%

This High-Yield Emerging Funds ETF Offers International Diversification

A 71-Year-Old’s $850,000 Home Is Her Biggest Retirement Asset. Downsizing Could Add $2,250 a Month

Celgene : CELG

All CELG Articles

Short Sellers Increase Bets in Major Biotechs

RBC Says These 4 Top Biotechs Could Have Big Upside Potential

Agios Files for Secondary Offering

Short Sellers Run for Cover From Major Biotechs

4 Key BioPharma Movers in the Past Week

Did Agios Just Speed Up Its Business Plan by 2 Years?

Short Sellers Increase Bets in Major Biotechs

How Much Medivation Can Really Fetch in a Buyout

Top Biotechs Are Among Jefferies Growth Stock Favorites

Short Sellers Run for Cover From Major Biotechs

Merrill Lynch Says the Time to Put Money Into Biotech Is Now

Top Analyst Upgrades and Downgrades: Apollo Global, ADM, Celgene, Total, Whole Foods, Targa Resources and More

RBC Says Buy Big Biotechs Now for Possible Big 2016 Gains

How Celgene Won With This Earnings Report

JPMorgan Bullish on Biotech: 3 Top Picks to Buy Now

This High-Yield Emerging Funds ETF Offers International Diversification

A 71-Year-Old’s $850,000 Home Is Her Biggest Retirement Asset. Downsizing Could Add $2,250 a Month

Why The Money Guy’s 25% Savings Rule Actually Starts at 15%

Featured Reads

A 71-Year-Old's $850,000 Home Is Her Biggest Retirement Asset. Downsizing Could Add $2,250 a Month

Why The Money Guy's 25% Savings Rule Actually Starts at 15%